SEC Form 4
Avalyn Pharma Inc. (AVLN) insider trading
In the 12 months to Nov 19, 2026, one AVLN insider reported open-market sales of $6.7M across 1 filing; 3 insiders bought $25.0M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $6.7M
- 1 filing · 1 insider
- Open-market purchases
- $25.0M
- 3 filings
Who traded AVLN, and when
- Purchase
- Sale
AVLN daily close from Apr 30, 2026 to Nov 18, 2026, between $23.33 and $39.25, last $27.69. 1 sale and 3 purchase filings by 4 insiders, marked at their filing dates. Novo Holdings A/S, 10% owner: bought $10.0M across 1 filing, first filed May 5, 2026, last May 5, 2026. Simeon George, 10% owner: bought $10.0M across 1 filing, first filed May 1, 2026, last May 1, 2026. FMR LLC, 10% owner: sold $6.7M across 1 filing, first filed Nov 12, 2026, last Nov 12, 2026. Jill Carroll, Director: bought $5.0M across 1 filing, first filed May 1, 2026, last May 1, 2026.
Largest mark · tap a row for others
Novo Holdings A/S · 10% owner
Purchase $9,999,990
555,555 shares at $18.00 avg
Filed May 5, 2026 · traded May 1
Close on filing date $27.43
Novo Holdings A/S · 10% owner
10% owner
$10.0M boughtSimeon George · 10% owner
10% owner
$10.0M boughtFMR LLC · 10% owner
10% owner
$6.7M soldJill Carroll · Director
Director
$5.0M boughtOpen-market trades
4 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Novo Holdings A/S | 10% owner | — | $10.0M | 1 | — | |
| Simeon George | 10% owner | — | $10.0M | 1 | — | |
| FMR LLC | 10% owner | $6.7M | — | 1 | — | |
| Jill Carroll | Director | — | $5.0M | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | FMR LLC 10% owner | Sale | 228,454 | $29.33 | $6.7M | 2,056,081 | |
traded | Novo Holdings A/S 10% owner | Purchase | 555,555 | $18.00 | $10.0M | 3,883,289 | |
traded | Simeon George 10% owner | Purchase | 555,555 | $18.00 | $10.0M | Multiple accounts | |
traded | Jill Carroll Director | Purchase | 277,778 | $18.00 | $5.0M | 2,186,562 |
GET /stocks/filings/vX/form-4?tickers=AVLN&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"AVLN"
],
"issuer_cik": "0001540171",
"owner_cik": "0000315066",
"accession_number": "0001193125-26-457571",
"form_type": "4",
"filing_date": "2026-11-12",
"period_of_report": "2026-11-09",
"issuer_name": "Avalyn Pharma Inc.",
"issuer_trading_symbol": "AVLN",
"owner_name": "FMR LLC",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-10",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 5565,
"transaction_price_per_share": 29.56,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 2103970,
"transaction_value": 164501.4,
"direct_or_indirect": "I",
"nature_of_ownership": "F-Prime Capital Partners Healthcare Fund V LP",
"footnotes": [
{
"id": "F3",
"description": "The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.82 to $29.81. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."
}
],
"remarks": "Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110.\nRemark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.\nRemark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager."
},
{
"tickers": [
"AVLN"
],
"issuer_cik": "0001540171",
"owner_cik": "0000315066",
"accession_number": "0001193125-26-457571",
"form_type": "4",
"filing_date": "2026-11-12",
"period_of_report": "2026-11-09",
"issuer_name": "Avalyn Pharma Inc.",
"issuer_trading_symbol": "AVLN",
"owner_name": "FMR LLC",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-09",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 173661,
"transaction_price_per_share": 29.06,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 2110874,
"transaction_value": 5046588.66,
"direct_or_indirect": "I",
"nature_of_ownership": "F-Prime Capital Partners Healthcare Fund V LP",
"footnotes": [
{
"id": "F1",
"description": "The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.65 to $29.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."
}
],
"remarks": "Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110.\nRemark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.\nRemark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 13 records
- Other13 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Avalyn Pharma Inc.'s CEO sold stock?
No. Lyn Baranowski (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is AVLN’s insider data?
These are AVLN Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track AVLN insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for AVLN every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.